Relay Therapeutics Inc (RLAY) financials
Relay Therapeutics revenue and earnings by year
Relay Therapeutics's revenue was $15.4 million in the fiscal year to December 31, 2025, up 53.4% from the year before. Net income was -$276 million, -1800.6% of revenue. Since the fiscal year to December 31, 2020, revenue has shrunk 28.6% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 6 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
| Revenue | 15 | 10 | 26 | 1 | 3 | 83 |
| Revenue growth | 53.4% | -60.8% | 1749.8% | -54.4% | -96.3% | — |
| Operating income | -303 | -386 | -379 | -311 | -362 | -56 |
| Operating margin | -1971.6% | -3854.0% | -1485.3% | -22516.4% | -11946.6% | -67.5% |
| Net income | -276 | -338 | -342 | -291 | -364 | -52 |
| Net margin | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% | -63.4% |
| Diluted EPS | -$1.61 | -$2.36 | -$2.79 | -$2.59 | -$3.85 | — |
| Free cash flow | -236 | -251 | -304 | -239 | -78 | -104 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open RLAY in Markets.
See also: RLAY returns
No forecast, no recommendation. This page describes Relay Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.